Compare StocksINTC vs MRNA

Intel Corporation (INTC) vs Moderna, Inc. (MRNA): Which Is the Better Buy in 2026?

As of 2026-06-19, INTC is overvalued at $134, with a DCF intrinsic value of $8 and a margin of safety of -1513%. MRNA is overvalued at $64, with an intrinsic value of $6 and a margin of safety of -963%. Of the two, MRNA has the wider margin of safety.

INTC
Intel Corporation
$133.99
VS
MRNA
Moderna, Inc.
$63.96

Risks

INTC
  • Intel Corporation scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.
  • Share count has increased by 21% over the past 4 years, diluting existing shareholders.
  • Insiders have sold $6.5M worth of stock in the past 3 months — significant insider liquidation.
MRNA
  • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
  • Gross margin of -69.9% is low, suggesting a competitive or commodity-like market with limited pricing power.
  • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.

Key Valuation Metrics

Learn more →
INTC
MRNA
Valuation
$-8.30B
Free Cash Flow
$-20.00M
-1.23%
FCF Yield
-0.08%
N/A
Trailing P/E
N/A
86.70
Forward P/E
-15.21
Quality & Moat
1.72%
ROIC
-26.47%
-2.91%
ROE
-36.56%
37.20%
Gross Margin
-69.89%
1.36
PEG Ratio
N/A
Balance Sheet Safety
0.10
Net Debt / Equity
Net cash
N/A
Interest Coverage
N/A
0.86
Net Debt / EBITDA
N/A
0.00%
Dividend Yield
0.00%
INTC: 3Ties: 1MRNA: 5
INTCMRNA

Historical Fundamentals

Learn more →
INTC

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

MRNA

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
INTC
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-22.02B
Δ Market Cap
+$74.94B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
MRNA
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-11.10B
Δ Market Cap
$-57.53B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
INTC
Insufficient Data
Enter initial FCF to calculate intrinsic value
Current Price: $133.99
Fair Value: $0.00
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
MRNA
962.8% Overvalued
Price is 962.8% above estimated fair value
Current Price: $63.96
Fair Value: $6.02
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
INTC

Requires positive FCF to compute implied growth rate.

MRNA

Requires positive FCF to compute implied growth rate.

Economic Moat Score

Learn more →
INTC
17/100
No Moat
70+ Wide · 40-69 Narrow · <40 None

No durable moat detected, though revenue predictability shows some competitive positioning. The business lacks consistent evidence of sustainable advantages.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
MRNA
17/100
No Moat
70+ Wide · 40-69 Narrow · <40 None

No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

Forensic Accounting

Learn more →
INTC
-2.83
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone
Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
MRNA

Insufficient data for Beneish M-Score calculation (requires 2+ years).

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
INTC
Insiders 14.7%Institutions 64.0%Retail & Other 21.2%
No. of Institutional Holders3,349
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
MRNA
Insiders 7.3%Institutions 78.9%Retail & Other 13.7%
No. of Institutional Holders1,044
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
INTC
0
Buys (3M)
1
Buys (12M)
Total value (12M): $249,985
ZINSNER DAVID A
Chief Financial Officer
$249,985
@ $42.50 · 2026-01-26
GELSINGER PATRICK P
Chief Executive Officer
$251,198
@ $22.53 · 2024-11-04
GELSINGER PATRICK P
Chief Executive Officer
$251,946
@ $20.16 · 2024-08-05
Open market purchases · includes direct & indirect ownership · excludes option exercises
MRNA
0
Buys (3M)
0
Buys (12M)
SAGAN PAUL L
Director
$1.00M
@ $31.76 · 2025-03-03
BANCEL STEPHANE J
Chief Executive Officer
$5.00M
@ $31.22 · 2025-03-03
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
INTC
2
Sells (3M)
3
Sells (12M)
Total value (12M): $7.47M
CHANDRASEKARAN NAGASUBRAMANIYAN
Chief Technology Officer
$2.49M
@ $118.28 · 2026-05-29
MILLER BOISE APRIL
Officer
$4.01M
@ $99.53 · 2026-05-01
MILLER BOISE APRIL
Officer
$981,000
@ $49.05 · 2026-02-02
HOLTHAUS MICHELLE JOHNSTON
General Counsel
$650,000
@ $26.00 · 2024-11-07
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
MRNA
3
Sells (3M)
6
Sells (12M)
Total value (12M): $11.57M
KLINGER SHANNON THYME
Officer
$173,550
@ $50.00 · 2026-06-04
HOGE STEPHEN
President
$2.58M
@ $48.40 · 2026-05-15
HUSSAIN SHAH ABBAS
Director
$264,952
@ $46.63 · 2026-05-01
KLINGER SHANNON THYME
Officer
$726,047
@ $52.29 · 2026-03-02
HOGE STEPHEN
President
$7.81M
@ $48.84 · 2026-02-23
HUSSAIN SHAH ABBAS
Director
$13,910
@ $27.60 · 2025-12-09
HUSSAIN SHAH ABBAS
Director
$8,736
@ $28.00 · 2025-06-11
KLINGER SHANNON THYME
Officer
$23,637
@ $44.68 · 2024-12-09
KLINGER SHANNON THYME
Officer
$4,849
@ $43.29 · 2024-12-03
HOGE STEPHEN
President
$13,595
@ $43.30 · 2024-12-03
KLINGER SHANNON THYME
Officer
$60,675
@ $42.79 · 2024-11-29
HOGE STEPHEN
President
$12,452
@ $42.79 · 2024-11-29
MOCK JAMES M
Chief Financial Officer
$60,761
@ $42.79 · 2024-11-29
HOGE STEPHEN
President
$12,771
@ $46.10 · 2024-11-11
MOCK JAMES M
Chief Financial Officer
$42,986
@ $60.12 · 2024-10-07
KLINGER SHANNON THYME
Officer
$40,539
@ $73.57 · 2024-09-09
KLINGER SHANNON THYME
Officer
$8,777
@ $76.99 · 2024-09-03
HOGE STEPHEN
President
$24,483
@ $76.99 · 2024-09-03
KLINGER SHANNON THYME
Officer
$12,640
@ $78.02 · 2024-08-29
HOGE STEPHEN
President
$23,408
@ $78.03 · 2024-08-29
MOCK JAMES M
Chief Financial Officer
$12,640
@ $78.02 · 2024-08-29
KLINGER SHANNON THYME
Officer
$104,722
@ $79.39 · 2024-08-28
MOCK JAMES M
Chief Financial Officer
$104,881
@ $79.40 · 2024-08-28
HOGE STEPHEN
President
$21,363
@ $84.11 · 2024-08-12
AFEYAN NOUBAR BOGHOS
Director
$1.80M
@ $119.96 · 2024-07-31
AFEYAN NOUBAR BOGHOS
Director
$1.77M
@ $117.80 · 2024-07-24
AFEYAN NOUBAR BOGHOS
Director
$1.84M
@ $122.84 · 2024-07-17
HOGE STEPHEN
President
$1.82M
@ $121.12 · 2024-07-15
AFEYAN NOUBAR BOGHOS
Director
$1.76M
@ $117.08 · 2024-07-10
MOCK JAMES M
Chief Financial Officer
$81,465
@ $118.24 · 2024-07-08
AFEYAN NOUBAR BOGHOS
Director
$1.91M
@ $127.22 · 2024-06-26
AFEYAN NOUBAR BOGHOS
Director
$2.00M
@ $133.57 · 2024-06-18
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
INTC
FearGreed
😏Greed(65/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
MRNA
FearGreed
😏Greed(61/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
INTC
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (65)
MRNA
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
View INTC Full AnalysisView MRNA Full Analysis

Frequently Asked Questions: INTC vs MRNA

Is Intel Corporation or Moderna, Inc. more undervalued in 2026?

Based on our discounted cash flow model, MRNA trades at a -962.8% margin of safety (intrinsic value $6 vs. price $64), compared to INTC's -1512.6% margin of safety (intrinsic $8 vs. $134).

Which stock has a wider economic moat, Intel Corporation or Moderna, Inc.?

MRNA scores 17/100 (None moat), while INTC scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is Intel Corporation in financial distress?

INTC's Altman Z-Score of 2.1 places it in the Grey zone, signaling elevated bankruptcy risk. MRNA scores 2.5 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which company has better free cash flow, Intel Corporation or Moderna, Inc.?

Moderna, Inc. (MRNA) generates a -0.1% free cash flow yield, compared to Intel Corporation's -1.2%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

Which stock has higher return on invested capital, Intel Corporation or Moderna, Inc.?

INTC earns 1.7% ROIC versus MRNA's -26.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

INTC vs MRNA: Which Is the Better Buy in 2026? | SafetyMargin.io